Zoetis Inc. $ZTS Shares Bought by Norris Perne & French LLP MI

Norris Perne & French LLP MI raised its holdings in Zoetis Inc. (NYSE:ZTS) by 24.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 63,050 shares of the company’s stock after purchasing an additional 12,534 shares during the quarter. Norris Perne & French LLP MI’s holdings in Zoetis were worth $7,933,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the fourth quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis in the third quarter valued at about $31,000. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $30,000. Finally, Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. Piper Sandler reissued a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $120.08 on Tuesday. The stock has a fifty day moving average price of $122.12 and a 200 day moving average price of $126.90. The stock has a market cap of $50.51 billion, a PE ratio of 19.95, a P/E/G ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.